Chandarlapaty, Sarat

Publications

Sort by

Co-Author Network

selected publications

Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹Zr-Pertuzumab PET/CT. Radiology. 2020 Academic Article GET IT
Times cited: 24
Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA oncology. 2020 Academic Article GET IT
Times cited: 49
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science (New York, N.Y.). 2019 Academic Article GET IT
Times cited: 136
Reversible histone glycation is associated with disease-related changes in chromatin architecture. Nature communications. 2019 Academic Article GET IT
Times cited: 96
Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2018 Academic Article GET IT
Times cited: 12
Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study. Journal of vascular and interventional radiology : JVIR. 2018 Academic Article GET IT
Times cited: 12
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. 2018 GET IT
Times cited: 73
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. 2018 GET IT
Times cited: 130
KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. Oncogene. 2018 Academic Article GET IT
Times cited: 72
Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial. Cancer. 2018 Academic Article GET IT
Times cited: 58
Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer discovery. 2017 Academic Article GET IT
Times cited: 191
Genomic profiling of ER⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science translational medicine. 2017 Academic Article GET IT
Times cited: 71
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast cancer research : BCR. 2017 Academic Article GET IT
Times cited: 42
OncoKB: A Precision Oncology Knowledge Base. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 394
AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 193
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. Oncoimmunology. 2017 Academic Article GET IT
Times cited: 57
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR⁺, HER2^- advanced breast cancer: results from BOLERO-2. British journal of cancer. 2017 Academic Article GET IT
Times cited: 94
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer discovery. 2016 Academic Article GET IT
Times cited: 222
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2016 Academic Article GET IT
Times cited: 210
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA oncology. 2016 Academic Article GET IT
Times cited: 321
Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. Cancer research. 2016 Academic Article GET IT
Times cited: 35
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer cell. 2016 Academic Article GET IT
Times cited: 146
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. Breast cancer research and treatment. 2016 Academic Article GET IT
Times cited: 28
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 130
Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 72
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. eLife. 2016 Academic Article GET IT
Times cited: 179
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 10
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Science translational medicine. 2015 Academic Article GET IT
Times cited: 396
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nature genetics. 2015 Academic Article GET IT
Times cited: 127
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Science translational medicine. 2015 Academic Article GET IT
Times cited: 232
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer cell. 2014 Academic Article GET IT
Times cited: 185
PTEN is a protein tyrosine phosphatase for IRS1. Nature structural & molecular biology. 2014 Academic Article GET IT
Times cited: 96
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. 2014 GET IT
Times cited: 155
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. 2014 GET IT
Times cited: 294
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 39
Molecular pathways: HER3 targeted therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Review GET IT
Times cited: 136
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer discovery. 2014 Academic Article GET IT
Times cited: 141
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clinical breast cancer. 2013 Academic Article GET IT
Times cited: 79
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast cancer research : BCR. 2013 Academic Article GET IT
Times cited: 77
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature genetics. 2013 Academic Article GET IT
Times cited: 813
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer cell. 2012 Academic Article GET IT
Times cited: 397
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 156
Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer discovery. 2012 Review GET IT
Times cited: 152
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 4
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer discovery. 2011 Academic Article GET IT
Times cited: 354
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer cell. 2011 Academic Article GET IT
Times cited: 917
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 347
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 241
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert review of anticancer therapy. 2011 Review GET IT
Times cited: 328
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011 Academic Article GET IT
Times cited: 416
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell. 2011 Academic Article GET IT
Times cited: 772
Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Applied immunohistochemistry & molecular morphology : AIMM. 2010 Academic Article GET IT
Times cited: 50
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 115
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. 2009 Academic Article GET IT
Times cited: 99
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PloS one. 2008 Academic Article GET IT
Times cited: 244
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer research. 2008 Academic Article GET IT
Times cited: 157
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 158
Ash1, a daughter cell-specific protein, is required for pseudohyphal growth of Saccharomyces cerevisiae. Molecular and cellular biology. 1998 Academic Article GET IT
Times cited: 58

more ...

less ...

Background

education and training

M.D., Wake Forest University School of Medicine 2002
Ph.D., University of North Carolina 1998
B.S., College of William and Mary 1993

Contact

full name

Sarat Chandarlapaty

primary email

chandars@mskcc.org

VIVO Weill Cornell Medical College

Sarat Chandarlapaty Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email